Key Points {#FPar1}
==========

Pegfilgrastim has been shown to be superior to filgrastim at reducing chemotherapy-related neutropenia and at achieving target dose intensity, as the latter is often under-dosed in clinical practice.Use of biosimilar pegfilgrastim will facilitate access and, supported by guidelines and clinical rules, enable the full potential of these life-saving benefits to be realised at reduced cost.

Introduction {#Sec1}
============

Febrile neutropenia (FN) is one of the most serious complications of cancer chemotherapy and can lead to fatal consequences, such as sepsis \[[@CR1]\]. FN further reduces cancer patient survival rates through delays, dose reductions and discontinuations of chemotherapy schedules \[[@CR2], [@CR3]\]. As well as being a medical emergency with significant clinical burden, the economic burden of FN, particularly related to hospitalisations, is substantial \[[@CR4], [@CR5]\]. Granulocyte colony-stimulating factors (G-CSFs) have been proven effective in reducing the incidence of FN and are recommended for the prevention of chemotherapy-induced neutropenia in international guidelines \[[@CR1], [@CR5]\]. There are two main types of G-CSF: filgrastim, which is administered daily during the chemotherapy cycle, and pegfilgrastim, a pegylated form of filgrastim, which allows administration once per cycle \[[@CR4]\]. Biosimilars of filgrastim have been available in Europe since 2008 \[[@CR6]\]. Biosimilars are lower-cost versions of already authorised reference medicines with comparable physicochemical and biological characterisation and clinical effectiveness and safety \[[@CR7]\]. The cost reductions induced by the introduction of biosimilar filgrastim has resulted in increased access to this therapy, with Sweden, for example, documenting a 5-fold increase in reimbursed usage \[[@CR6]\]. In New Zealand, expanded use of G-CSF as primary rather than secondary prophylaxis following the introduction of biosimilar filgrastim has seen the number of breast cancer patients hospitalised due to chemotherapy-induced FN decline from one third of women to \< 7% \[[@CR8]\]. The first pegfilgrastim biosimilars were approved in Europe in September 2018 and in the US in November that year; there are currently seven such products approved in Europe and three in the US (Table [1](#Tab1){ref-type="table"}). This review aims to explore whether biosimilar pegfilgrastim will have a similar impact to that of biosimilar filgrastim and further improve clinical outcomes and cost effectiveness in patients undergoing cytotoxic chemotherapy.Table 1Biosimilars of pegfilgrastim approved in Europe and the USBrand nameManufacturerRegistration trialEMA approvalFDA approvalPelgraz^®^Accord HealthcareDesai et al. 2018 \[[@CR56]\] Phase III randomised, assessor-blinded, multicentre study on 589 breast cancer patients with reference arms of US--Neulasta and EU--NeulastaSeptember 2018Udenyca^®^CoherusDose--response trial^a^September 2018November 2018Fulphila^®^MylanWaller et al. 2019 \[[@CR57]\] Phase III randomised, assessor-blinded study on 194 breast cancer patients with reference arm of EU--NeulastaNovember 2018June 2018Pelmeg^®^Cinfa Biotech/MundipharmaDose-response trial^a^November 2018Ziextenzo^®^SandozHarbeck et al. 2016 \[[@CR58]\] Phase III randomised, assessor-blinded, multicentre study on 316 breast cancer patients with reference arm of EU--NeulastaNovember 2018November 2019Grasustek^®^Juta PharmaGrasustek (EPAR)^b^ Phase III randomised, assessor-blinded, multicentre study on 254 breast cancer patients with reference arm of EU--NeulastaApril 2019Pegfilgrastim Mundipharma^®^MundipharmaDose-response trial^a^December 2019^a^As reported in EMA EPAR available at <https://www.ema.europa.eu>^b^EMA Grasustek EPAR. Available at <https://www.ema.europa.eu/en/medicines/human/EPAR/grasustek>*EMA* European Medicines Agency, *EPAR* European public assessment report, *FDA* The Food and Drug Administration

Methods {#Sec2}
=======

This narrative review was developed by oncologists (MA, PC and PG) and a pharmacist (AV) who are experts in G-CSF and biosimilars and have published widely on the subject matter. Two of the authors (PC and PG) have recently published a systematic review and meta-analysis of all trials of G-CSF or pegfilgrastim for both randomised and non-randomised comparisons using Cochrane methodology \[[@CR4]\]. A further non-systematic review of the relevant literature in PubMed and the Cochrane Library was undertaken, which was supplemented by studies identified by the authors. The importance of G-CSF as primary prophylaxis for chemotherapy-induced neutropenia and the role of pegfilgrastim was summarised and recommendations on the implementation of biosimilar pegfilgrastim provided, predicated on the best available evidence and the authors' experiences with (biosimilar) G-CSF and biosimilars in general.

Burden of Febrile Neutropenia {#Sec3}
=============================

FN is one of the most feared complications of chemotherapy and is classed as a medical emergency \[[@CR5]\].

FN is defined by the European Society of Medical Oncology (ESMO) as "an oral temperature of \> 38.3 °C or two consecutive readings of \> 38.0 °C for 2 h and an absolute neutrophil count (ANC) of \< 0.5 × 10^9^/L, or expected to fall below 0.5 × 10^9^/L" \[[@CR5]\]. It has been estimated that the incidence of FN might be as high as 117 cases per 1000 cancer patients \[[@CR9]\]. FN causes a significant medical burden, with up to 30% of cases requiring inpatient hospital care and mortality rates in the range of 2--21% \[[@CR5], [@CR10]\]. In 2012, the Office of National Statistics reported approximately two deaths per day in England and Wales from neutropenic sepsis \[[@CR11]\]. Patients spend an average of 9--10 days in hospital per neutropenic episode \[[@CR12], [@CR13]\]. The economic consequences of FN are substantial, with ESMO estimating in 2016 that the mean cost of an FN hospitalisation in Western countries was approximately €13,500 \[[@CR5]\].

Benefits of Granulocyte Colony-Stimulating Factor (G-CSF) Prophylaxis {#Sec4}
=====================================================================

G-CSFs are biological growth factors that stimulate the production, differentiation and activation of neutrophils in the bone marrow, thereby reducing the risk, severity and duration of neutropenia \[[@CR2], [@CR10]\]. A key factor when considering G-CSF is the ANC nadir (the lowest value to which the neutrophil count will fall following drug administration); if the nadir depth and duration can be limited, there are less likely to be complications or chemotherapy dose reductions and delays from neutropenia \[[@CR14], [@CR15]\]. To minimise the ANC nadir, filgrastim is administered as a daily dose of 5 µg/kg at least 24 hours after each chemotherapy administration and within 3--4 days after cycle completion. Pegfilgrastim is given as one 6-mg dose per cycle and should be administered the day after initiating chemotherapy; however, administration up to 3--4 days after initiation may also be reasonable \[[@CR5], [@CR16]--[@CR18]\].

Prophylactic use of G-CSF reduces the incidence of FN and infection-related mortality whilst, importantly, maintaining the relative dose intensity (RDI) of chemotherapy and, thereby, improving cancer outcomes \[[@CR19], [@CR20]\]. RDI has a major influence on the efficacy and survival rates of patients receiving chemotherapy for chemo-sensitive tumours. A clear dose--response effect of adjuvant chemotherapy was first demonstrated by Bonadonna and Valagussa in 1981 \[[@CR21]\] and confirmed at the 20-year follow-up \[[@CR22]\]. In the UK SPROG trial (A Randomised Trial of Secondary Prophylaxis using Granulocyte Colony Stimulating Factor), it was reported that 75% of patients with breast cancer received their target of 85% planned RDI of adjuvant chemotherapy with 7 days of filgrastim or pegfilgrastim, compared with only 50% of those not receiving G-CSF (*p* \< 0.0001) \[[@CR23]\]. Findings from a meta-analysis provide the most compelling evidence of the importance of G-CSF to cancer outcomes. In this analysis of data from 61 randomised controlled trials (RCTs) involving 11,337 patients who received G-CSF and 13,456 controls, G-CSF was found to increase absolute cancer survival rates by 3.2% \[[@CR24]\]. To put this into context, this compares with a 2--3% absolute survival benefit for adjuvant chemotherapy given to early-stage, node-negative breast cancer patients aged 50--69 years \[[@CR25]\]. The importance of the impact of G-CSF on long-term cancer outcomes is recognised by its status as a World Health Organization (WHO) Essential Drug, meaning that it should be provided with sufficient reimbursement to be accessed for free, or at prices affordable to all \[[@CR26]\].

G-CSF Guidelines {#Sec5}
================

Established guidelines regarding G-CSF use in the prevention of chemotherapy-induced FN have been issued by ESMO, the European Organisation for Research and Treatment of Cancer (EORTC), the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) \[[@CR1], [@CR5], [@CR16], [@CR17]\]. G-CSF is recommended as primary prophylaxis of chemotherapy-induced neutropenia when the overall risk of FN for the prescribed regimen is ≥ 20% (Fig. [1](#Fig1){ref-type="fig"}). For patients prescribed chemotherapy with a 10--20% risk of FN, G-CSF use should be considered in those with additional risk factors placing them at enhanced risk, such as age \> 65 years, coexisting morbidities or prior history of FN. Patients on low-risk regimens (\< 10% risk of FN) are not recommended G-CSF prophylaxis. If primary prophylaxis was not prescribed, G-CSF is recommended as secondary prophylaxis for patients who have had a neutropenic complication from a previous cycle of chemotherapy \[[@CR1], [@CR5], [@CR16], [@CR17]\]. However, it should be noted that the majority of neutropenic complications occur in the earliest cycles of chemotherapy; for example, across two trials involving high-risk breast cancer patients, the incidence of grade 4 neutropenia in cycle 1 was approximately 80%, but fell to 50% by cycle 4 \[[@CR14], [@CR27]\]. Such data emphasises the importance of primary as opposed to secondary G-CSF prophylaxis \[[@CR28]\].Fig. 1Algorithm for assessing FN risk and the need for primary prophylactic G-CSF. Adapted from guidelines by the European Organisation for Research and Treatment of Cancer \[[@CR1]\], the European Society of Medical Oncology \[[@CR5]\] and the National Comprehensive Cancer Network \[[@CR16]\]. *FN* febrile neutropenia, *G-CSF* granulocyte-colony stimulating factor

Primary prophylaxis with G-CSF should start with the first cycle of chemotherapy and continue throughout subsequent cycles \[[@CR1], [@CR5], [@CR16], [@CR17]\]. ESMO recommends administration of filgrastim for around 10 days \[[@CR5]\], whilst a recently published expert consensus recommends that pegfilgrastim should always be administered in preference to a duration of daily filgrastim of \< 11 days \[[@CR9]\]. Pegfilgrastim use is supported in different length chemotherapy cycles, including fortnightly, albeit data are more limited in patients receiving weekly regimens, where filgrastim might be preferred \[[@CR9]\]. For patients on chemotherapy at a high risk of FN (≥ 20%) or intermediate risk of FN (10--20%) plus additional risk factors, pegfilgrastim is generally considered the G-CSF of choice to maintain RDI and avoid the severe complications associated with FN, due to the simplified administration compared with filgrastim supporting higher adherence and, therefore, coverage of the ANC nadir \[[@CR9], [@CR29]\].

The availability of biosimilar pegfilgrastim offers a fresh opportunity to ensure the proper application of these guidelines. A multidisciplinary approach is required both for the implementation of evidenced-based guidelines as well as the adoption of biosimilars into day-to-day practice, and these processes can be linked to mutual benefit. Four key principles can help guide the implementation of biosimilars within a region or country:Multi-stakeholder approach: involve everybody from top to bottom in your healthcare setting and educate about biosimilars.One-voice principle: the whole team should talk about biosimilars in a positive way and avoid sending confused or mixed messages (this will greatly reduce any nocebo effect).Shared decision making: inform the patient about the fact that treatment is initiated/continued with a biosimilar, an equally effective and safe alternative.Gain sharing: introduction of biosimilars requires extra effort (= time) from busy healthcare professionals. A part of the savings from biosimilars should benefit the clinical department that generate the savings.

This process, for example, could be led by a pharmacist, involving presentations and discussions with the oncology physicians and nursing staff. Computer order systems for anticancer therapies could be leveraged to link biosimilar pegfilgrastim to chemotherapy regimens with a high risk of FN. In this way, implementation of the G-CSF guidelines can be assured as well as the adoption of biosimilar pegfilgrastim into routine practice. It cannot be overstressed the importance that all healthcare professionals involved in the care of cancer patients are in agreement about when to use G-CSF support and the use of biosimilar pegfilgrastim to ensure an efficient and long-term solution. The use of clinical rules, whereby pharmacists work collaboratively with physicians to ensure guidelines are implemented, will support and facilitate this.

Pegfilgrastim Versus Filgrastim {#Sec6}
===============================

Numerous studies have compared the efficacy and safety of pegfilgrastim and filgrastim \[[@CR4], [@CR15], [@CR30]--[@CR32]\]. A recent meta-analysis identified 36 studies that reported a direct, head-to-head comparison of pegfilgrastim versus filgrastim \[[@CR4]\]. In 12 RCTs, the relative risk (RR) of developing FN was lower for pegfilgrastim compared with filgrastim, but the difference was not statistically significant (0.86; *p* = 0.226). Importantly, however, in 24 non-RCTs, the overall risk was significantly lower with pegfilgrastim than filgrastim for the incidence of FN (RR 0.67; *p* = 0.023), FN-related hospitalisations (RR 0.68; *p* \< 0.05) and chemotherapy dose delays (RR 0.68; *p* = 0.020). It was postulated by the authors that the greater efficacy of pegfilgrastim in non-RCTs might reflect under-dosing of filgrastim in routine clinical practice, as reflected in 11 of 12 RCTs that administered seven or more doses of short-acting G-CSF versus only 2 of 24 non-RCTs \[[@CR4]\]. When dosed equivalently (one dose of pegfilgrastim and 10--14 days of filgrastim), the safety profiles (e.g. bone pain) have been shown to be similar \[[@CR31]\].

Several studies have reported that under-dosing of filgrastim is prevalent in routine clinical practice \[[@CR33]--[@CR37]\]. Under-dosing of filgrastim has been reported in 17.4% of patients in Europe \[[@CR37]\], with the median schedule used being only 5 days \[[@CR38]\]. Under-dosing by weight is also common practice, with a German study reporting that approximately three-quarters of patients received the 300-µg (30-MU) dose of filgrastim (recommended for body weight up to 60 kg), when the average body weight (in Germany) is 75.6 kg \[[@CR35]\].

There are a number of possible reasons for the widespread under-dosing of filgrastim. A key reason is likely to be that filgrastim has always been available in a pack of five and from the earliest days of its use, patients were often prescribed one pack of 300 µg for reasons of cost and convenience. Although the advent of biosimilar filgrastim has removed or at least significantly diminished the cost element, it appears to still be habitual practice to prescribe a single pack of five \[[@CR35]\]. A survey of healthcare professionals (HCPs) from six European countries (Germany, Italy, Portugal, Poland, Lithuania and Latvia) undertaken in early 2019 to support this review found that almost half (48%; 42/88) of HCPs (89% physicians; 11% pharmacists) did not follow weight-based dosing of filgrastim and nearly two-thirds (64%; 56/88) prescribed a course of \< 7 days (Fig. [2](#Fig2){ref-type="fig"}). The reason is fundamentally simple: physician and pharmacist co-responsibility for proper use has not been implemented in the majority of hospitals. Patient adherence with the filgrastim regimen is another potentially salient reason for under-dosing. Lack of physician familiarity or awareness of the G-CSF guidelines and/or the consequences of FN on RDI and, thereby, cancer survival is likely to be another factor behind under-dosing of filgrastim and under use of G-CSF in general \[[@CR39]--[@CR41]\]. In Germany, for example, despite 85.1% of 195 physicians stating that they followed G-CSF guidelines, evidence revealed only 15.4% adherence for high-risk lung cancer patients and \< 50% for intermediate-risk lung and breast cancer patients \[[@CR41]\]. Lack of risk factors was cited by over half the physicians as a reason for not using G-CSF in patients prescribed a chemotherapy with a FN risk ≥ 20% \[[@CR41]\], yet the assessment of risk factors in this group of patients is unnecessary and only required for intermediate- or low-risk groups \[[@CR1], [@CR5], [@CR16]\]. Overall, it has been reported that as many as 80% of patients do not receive primary prophylaxis with G-CSF in accordance with their assessed risk \[[@CR39], [@CR41]\]. Dose reductions of chemotherapy related to neutropenia and use of G-CSF only as secondary prophylaxis have also been found to be widespread in clinical practice \[[@CR39], [@CR41]\].Fig. 2European survey results highlighting the under-dosing of filgrastim by both weight and duration of therapy. The survey of 88 healthcare professionals (78 physicians; 10 pharmacists) from six European countries (Germany *n* = 3; Italy *n* = 7; Portugal *n* = 31; Poland *n* = 29; Lithuania *n* = 12; Latvia *n* = 6) was undertaken in April--May 2019. Respondents were based in oncology clinics (*n* = 3); general hospitals (*n* = 36); or specialist haematology or oncology centres (*n* = 48). *HCPs* healthcare professionals

This widespread reporting of under-dosing (by weight-adapted dose and duration of therapy), with lack of adherence to both prescribing guidelines and the approved drug label for G-CSF, is striking. Given the proven impact of filgrastim on cancer cure, it is hard to imagine that such a situation would be considered appropriate for other aspects of curative cancer treatment, such as radiation or chemotherapy doses and schedules \[[@CR24]\].

Awareness and adherence to G-CSF guidelines can be improved through educational workshops, training courses and lectures, as demonstrated in Germany, where such interventions increased G-CSF use in alignment with guidelines from 15.4 to 47.8% in high-risk FN lung cancer patients undergoing chemotherapy \[[@CR42]\]. Whilst initiatives such as this represent a good start, more still needs to be done as adherence rates of \< 50% remain unacceptable, since this can jeopardise patient survival by increasing the risk of hospitalisations with neutropenic complications and the likelihood of interruptions to or discontinuation of chemotherapy treatment. The goal is to change practice in the long term and this requires a multidisciplinary approach with multiple forms of interventions. One of the most successful strategies to improve clinical practice and quality of care are clinical rules, whereby pharmacists support physicians by ensuring complete execution of a clinical protocol, such as the addition of laxatives when prescribing opioids. A concerted, pan-European programme, driven by a key society such as ESMO together with the European Association of Hospital Pharmacists (EAHP) and supported by individual country initiatives or national associations, is recommended to maximise the potential of G-CSF therapy to improve cancer cure rates and survival.

Pegfilgrastim offers distinct advantages over filgrastim in supporting adherence to G-CSF guidelines and in helping to ensure patients obtain sufficient G-CSF coverage during their chemotherapy. As a single 6-mg dose per cycle, pegfilgrastim obviates any weight-based dosing errors and insufficient duration of use that can occur with filgrastim \[[@CR4], [@CR5]\]. In addition, the once-per-cycle administration of pegfilgrastim may increase patient adherence, as the need for daily administration, daily hospital visits and regular testing of ANC levels is eliminated \[[@CR9]\]. Fewer hospital visits might also improve patient quality of life, particularly for older or frail patients, and reduce the risk of nosocomial infections, as well as saving the associated hospital resource use. Adherence to G-CSF guidelines has been shown to be higher with pegfilgrastim than filgrastim. In an Italian observational study of 645 consecutive patients and 3150 chemotherapy administrations, it was revealed that physicians were more likely to follow guidelines with pegfilgrastim compared with short-acting G-CSF (66% vs 47%, respectively; *p* = 0.002) \[[@CR43]\]. Furthermore, pegfilgrastim was administered at the correct time in 93.2% of patients compared with only 61.5% of patients receiving short-acting G-CSF (*p* \< 0.0001) \[[@CR43]\]. There is also some evidence that pegfilgrastim might improve RDI of chemotherapy compared with filgrastim. In the SPROG trial, 84.9% of breast cancer patients who received pegfilgrastim as secondary prophylaxis achieved 85% planned RDI of adjuvant chemotherapy compared with 69.5% of patients on 7 days of filgrastim (no *p* value reported) \[[@CR23]\].

Assessing the Value of Biosimilar Pegfilgrastim {#Sec7}
===============================================

As cancer incidence continues to rise and the costs of novel therapies ever increase, the need to find cheaper but equally effective therapies is paramount for the sustainability of healthcare systems. Biosimilars are as clinically effective as reference products and can be \> 30% cheaper, with cumulative savings across the five major European Union (EU) markets and the US estimated to reach €50--100 billion between 2016 and 2020 \[[@CR44]\]; creating headroom in healthcare budgets for new medicines. Since 2006, 58 biosimilars have been approved in Europe, including six biosimilars of filgrastim \[[@CR45]\]. As a result of the introduction of biosimilars, access to biologics has increased by as much as 100% in the EU \[[@CR44]\]. Initial concerns surrounding the efficacy and safety of biosimilars and the risks surrounding extrapolation of data and immunogenicity have proven to be completely unfounded \[[@CR6], [@CR46], [@CR47]\]. In a decade of use, biosimilar filgrastim has proven to be equally as effective and well tolerated as reference filgrastim, whilst providing cost savings (conservatively estimated to be 39% in Europe), increased access and a resultant decrease in FN-related hospitalisations \[[@CR6], [@CR8], [@CR48], [@CR49]\]. The recent licensing in Europe of seven biosimilar pegfilgrastim-containing products (as of December 2019) offers the opportunity to deliver the additional advantages of long- over short-acting G-CSF at a reduced cost. Biosimilar pegfilgrastim costs approximately €650 and filgrastim €100 per dose (based on list prices in the UK and France) \[[@CR50], [@CR51]\], meaning that at least six or seven doses of biosimilar filgrastim need to be prescribed to achieve price parity (with the caveat that any local or regional discounts etc. may affect this ratio). Hence, different approaches to adoption of biosimilar pegfilgrastim may be required depending on whether a country/jurisdiction is using predominantly reference pegfilgrastim or biosimilar filgrastim.

For countries using predominantly filgrastim biosimilars, the advantages of biosimilar pegfilgrastim are manifest in the simplified once-per-cycle dosing; improving adherence and appropriate coverage of the ANC nadir, and, thereby, fewer neutropenic events and FN-related deaths, increased RDI and improved cancer survival. All countries currently using filgrastim are urged to audit current usage to determine if under-dosing is commonplace, by number of doses and/or weight, and the implications of this on planned chemotherapy schedules and RDI (See Online Resource 1 in the electronic supplementary material for a suggested minimum dataset). Data from such audits should be taken into account when considering the relative costs versus benefits of biosimilar pegfilgrastim and biosimilar filgrastim. If a country is using the appropriate dosage of filgrastim (10--14 days), it may be that direct cost savings can be achieved with the introduction of biosimilar pegfilgrastim (e.g. €1000--€1400 vs €650 per cycle, respectively, using the prices quoted above).

For countries currently using reference pegfilgrastim, there are evident cost savings to be made of \> 30% or more by switching to biosimilar pegfilgrastim, which could support increased access to this important therapy and/or free up additional funds in the cancer drugs budget \[[@CR44]\]. The introduction of biosimilar pegfilgrastim will also increase competition in those countries using predominantly lipegfilgrastim, a second-in-class long-acting G-CSF.

In terms of choice of biosimilar pegfilgrastim, competition between manufacturers will likely result in the products being priced similarly, as is seen with biosimilars in other therapeutic areas. Assuming price parity, the choice of biosimilar may come down to a choice of device, as this can have a potentially strong influence on adherence. It is well known across all areas of medicine that patient anxiety and fear of needles can lead to poor adherence \[[@CR52]--[@CR54]\]. The biosimilar pegfilgrastim considered to have the most easy-to-use device, for example, with a shorter and smaller diameter or hidden needles, would likely lead to improved adherence \[[@CR54]\]. Processes to ensure that the rubber plunger does not stiffen with age and increase friction and, thereby, cause problems with delivery of the full dose are also a key consideration \[[@CR55]\]. A simple, patient-friendly device would likely increase patients' willingness to self-administer at home, as well as increase the efficiency of nurse delivery; which could provide further cost savings. Improving adherence to G-CSF therapy, and thereby optimising chemotherapy treatment and improving outcomes, could result in substantial savings in the cost of disease management and should be considered when deciding upon which pegfilgrastim biosimilar to prescribe.

Conclusions {#Sec8}
===========

Primary prophylaxis with G-CSF for patients on high-risk (≥ 20%) chemotherapies, or those on intermediate-risk (10--20%) chemotherapies plus additional risk factors, is critical to improving cancer patient survival by ensuring dose intensity of cancer therapy is maintained. It would be unacceptable for patients not to receive their full course of adjuvant radiotherapy, and the same standard should apply for chemotherapy. In clinical practice, the use of pegfilgrastim has been shown to be clinically superior to filgrastim at reducing neutropenic events and FN \[[@CR4]\], improving adherence to G-CSF guidelines \[[@CR43]\] and at achieving target RDI \[[@CR23]\], as the latter is frequently under-dosed \[[@CR4], [@CR36], [@CR37]\]. Biosimilar pegfilgrastim offers a fresh opportunity to rethink neutropenia management and the value of G-CSF in 2020, based on the significant potential for both clinical and economic benefits (Table [2](#Tab2){ref-type="table"}). A concerted, multidisciplinary action, involving prescribing physicians, oncology nurses and pharmacists, supported by guidelines and clinical rules, will release the full potential of this life-saving strategy.Table 2Key clinical and economic benefits offered by biosimilar pegfilgrastimClinical benefits vs filgrastim (\< 7 days)Economic benefits vs reference pegfilgrastimReduced FN incidenceCost savings \> 30%Reduced FN-related hospitalisationsIncreased patient accessReduced chemotherapy dose delaysCreate additional budget for new medicinesImproved relative dose intensityFinancial sustainabilityImproved adherence to G-CSF guidelinesImproved device/additional handling featuresReduced hospital visits and risk of nosocomial infectionsImproved patient acceptability and adherence*FN* febrile neutropenia, *G-CSF* granulocyte colony-stimulating factors
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